Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Tian-Mei Si, Ph.D
- Phone Number: 861062723748
- Email: sitianmei@bjmu.edu.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100191
- Recruiting
- Peking University Sixth Hospital
-
Contact:
- Tianmei Si, PhD., MD.
- Phone Number: 861062723748
- Email: si.tian-mei@163.com
-
Beijing, Beijing, China, 100096
- Recruiting
- Beijing Huilongguan Hospital
-
Contact:
- Lin Chen, MD.
- Phone Number: 86-13811004849
- Email: chl0175@163.com
-
Beijing, Beijing, China, 100035
- Recruiting
- Beijing Xicheng District Pingan Hosptial
-
Contact:
- Bai Han, MD.
- Phone Number: 86-10-66250226
- Email: hanbai@126.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Major depressive disorder according to Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-5);
- Age: 18-55 (including 18 and 55)
- HAMD-17≥18
- DARS ≤ 28
- Do not receive repetitive Transcranial Magnetic Stimulation (rTMS) or modified electroconvulsive therapy (MECT) treatment in past six months.
- Sign the informed consent form voluntarily and agree to participate in all visits, examinations and treatment as required by the trial protocol.
Exclusion Criteria:
- Patients who are diagnosed with major somatic diseases;
- Patients who meet DSM-5 diagnostic criteria for other mental disorders: Personality disorder, mental retardation; drug and/or alcohol dependence;
- Patients with severe suicidal tendencies or suicidal behavior;
- Pregnant or lactating women;
- Patients with MRI contraindications;
- Patients who are regarded as unsuitable by investigators for this clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Escitalopram
Escitalopram monotherapy (10-20 mg/day)
|
Escitalopram
|
|
Experimental: Escitalopram + omega-3 PUFAs
Escitalopram (10-20 mg/day)combined with omega-3 PUFAs (EPA 900mg,DHA 300 mg)
|
Escitalopram+omega-3 PUFAs
|
|
Experimental: Escitalopram + Aripiprazole
Escitalopram (10-20 mg/day)combined with Aripiprazole (2.5-10 mg/day)
|
Escitalopram+Aripiprazole
|
|
Experimental: Escitalopram + omega-3 PUFAs + Aripiprazole
Escitalopram (10-20 mg/day)combined with omega-3 PUFAs (EPA 900mg,DHA 300 mg)and Aripiprazole (2.5-10 mg/day)
|
Escitalopram+Aripiprazole+omega-3 PUFAs
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
17-item Hamilton depression rating scale (HAMD-17) value
Time Frame: Day 0 to Day 56
|
The value of 17-item Hamilton depression rating scale (HAMD-17) total score treatment compared to that at the baseline.
The maximum score of HAMD-17 is 51 and the minimum is 0. Higher scores mean a worse outcome.
|
Day 0 to Day 56
|
|
Anhedonia level-Dimensional Anhedonia Rating Scale (DARS)
Time Frame: Day 0 to Day 56
|
The outcome is measured by Dimensional Anhedonia Rating Scale (DARS) total score.
The maximum score of DARS total score is 68 and the minimum is 0. Higher scores mean a better outcome.
|
Day 0 to Day 56
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anxiety symptoms
Time Frame: Day 0 to Day 14, Day 0 to Day 28, Day 0 to Day 56
|
The outcome is measured by Hamilton anxiety rating scale (HAMA) total score change.
The change value of HAMA total scores at each timepoints compared to the baseline.
The maximum score of HAMA is 56 and the minimum is 0. Higher scores mean a worse outcome.
|
Day 0 to Day 14, Day 0 to Day 28, Day 0 to Day 56
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
cognition outcome
Time Frame: Day 0 to Day 56
|
The outcome is measured by cognition task.
|
Day 0 to Day 56
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Nervous System Diseases
- Mood Disorders
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Depression
- Depressive Disorder
- Anhedonia
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agonists
- Dopamine Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Antidepressive Agents, Second-Generation
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Selective Serotonin Reuptake Inhibitors
- Aripiprazole
- Citalopram
- Dexetimide
- Escitalopram
Other Study ID Numbers
Other Study ID Numbers
- 2022-1-4111
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.